Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 13/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89695 | 1.00 | REN (0.53) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL89242 | 0.99 | REN (0.53) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL89221 | 0.93 | REN (0.53) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL90633 | 0.92 | REN (0.55) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL90650 | 0.91 | REN (0.54) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL90632 | 0.91 | REN (0.57) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL8235431 | 0.91 | REN (0.57) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL90079 | 0.90 | REN (0.54) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL89840 | 0.90 | REN (0.55) | RENALDH1A1POLBGAASMN1; SMN2 | |
| SCHEMBL89812 | 0.90 | REN (0.54) | RENALDH1A1POLBGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | REN 1/4885ALDH1A1 38/4885POLB 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.